Mayo Biomarker Portfolio Summary

- Advanced prostate and kidney cancer (gene expression markers)
- Renal cell carcinoma (B7-H1 serum and tissue marker)
- Irritable bowel syndrome, eosinophilic esophagitis (EPX antibody)
- Companion theranostic for BCG bladder cancer therapy (EPX antibody)
- Cytidine analog efficacy (pharmacogenetics)
- FTLD, ALS (C9ORF72 non-coding repeat and MetOH)
- Endometrial cancer screening (microbiome-based)
- Rheumatoid arthritis treatment selection (microbiome-based)
- Prostate cancer progression gene panel
- Cancer (aquaporin antibodies)
- Irritable bowel syndrome (molecular markers)
- Preeclampsia (urine marker)\(^1,2\)
- Neuromyelitis optica (aquaporin antibody)

Discovery

- Breast cancer recurrence (gene expr. markers)
- Prostate cancer detection
- Acute cellular rejection (serum markers)
- Ovarian cancer (proMBP)
- Amyloidosis (urine exosomes)
- Cancer (Akt regulation)
- Cancer (p53 regulation)
- Cancer/sepsis immune suppression (cell markers)
- Cancer markers (phagocytized DNA)

Verification

- Atherosclerosis (PAPP-A)\(^2\)
- Aero-digestive malignancies (stool-based screen)\(^1\)
- Rheumatoid arthritis/CV co-morbidity (cytokine panel)
- Prostate cancer prognosis (tissue markers)
- Renal disease (serum/urine CNP)
- CV medications (pharmacogenetics)
- Prostate cancer progression/survival (B7-H3)
- Aortic valve and vessel stenosis marker (cEPCs)\(^2\)
- Colorectal cancer risk in IBD patients (gene markers)
- Methylation markers (lung/pancreatic cancer)

Pilot Validation

- sDNA testing for CRC\(^1,4\)
- Genome analytics\(^4\)
- Psychotropic medication efficacy (pharmacogenetics)\(^1,2,4\)

Test Development / Validation

- Mayo DTF Funded
- Mayo ILP Funded
- MN Partnership Funded
- MMV fund

Clinical Development

\(^1\) Mayo DTF Funded  \(^2\) Mayo ILP Funded  \(^3\) MN Partnership Funded  \(^4\) MMV fund

\(\text{●} = \text{Unlicensed}  \quad \text{●} = \text{Licensed}\)